Harbin Medisan Pharmaceutical Co Ltd
SZSE:002900
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Harbin Medisan Pharmaceutical Co Ltd's latest stock split occurred on Jun 13, 2018
The company executed a 1-for-1 stock split, meaning that for every share held, investors received 1 new share.
Before the split, Harbin Medisan Pharmaceutical Co Ltd traded at 22.74 per share. Afterward, the share price was about 18.8167.
The adjusted shares began trading on Jun 13, 2018. This was the only stock split in Harbin Medisan Pharmaceutical Co Ltd's history.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 28, 2026
|
|
Kura Sushi Inc
TSE:2695
|
2-for-1
x2
|
3565 1782.5 JPY | 1745 1745 JPY |
|
Apr 28, 2026
|
|
Sanki Engineering Co Ltd
TSE:1961
|
3-for-1
x3
|
7020 2340 JPY | 2413 2413 JPY |
|
Apr 28, 2026
|
|
Hyterra Ltd
ASX:HYT
|
65-for-64
x1.015625
|
0.015 0.0148 AUD | 0.015 0.015 AUD |
|
Apr 28, 2026
|
|
Fit Corp
TSE:1436
|
3-for-1
x3
|
4065 1340 JPY | 1269 1269 JPY |
|
Apr 28, 2026
|
|
Visual Processing Japan Co Ltd
TSE:334A
|
2-for-1
x2
|
1844 922 JPY | 965 965 JPY |
2695
1961
HYT
1436
334A
Harbin Medisan Pharmaceutical Co Ltd
Glance View
Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of chemical medicine preparations. The company is headquartered in Harbin, Heilongjiang and currently employs 1,519 full-time employees. The company went IPO on 2017-09-22. Its medicines cover the nervous system, cardio-cerebrovascular, systemic anti-infection, musculoskeletal, nutritional infusion, and body fluid balance infusion therapeutic fields. The firm's products include freeze-dried powder injections, small volume injections, large infusion products, solid preparations, medical devices and cosmetics. The firm mainly distributes its products within domestic market.
